Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Type 2 diabetes mellitus~* On a stable dose of metformin (≥1500 mg/day) for at least 12 weeks with inadequate glycemic control~* Females of reproductive potential agree to remain abstinent or use or have their partner use acceptable methods of birth control~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* Treated with any antihyperglycemic agents (AHA) therapies other than the protocol-required metformin within the prior 12 weeks of study participation or with omarigliptin at any time prior to signing informed consent~* On a weight loss program and is not in the maintenance phase or has~started a weight loss medication in the past 6 months or has undergone bariatric surgery within 12 months prior to study participation~* Medical history of active liver disease (other than non-alcoholic~hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease~* Human immunodeficiency virus~* New or worsening coronary heart disease, congestive heart failure, myocardial infarction, unstable angina, coronary artery intervention, stroke or transient ischemic neurological disorder within the past 3 months~* History of malignancy ≤5 years prior to study participation except for adequately treated basal cell or squamous cell skin cancer, or in situ~cervical cancer~* Clinically important hematological disorder (such as aplastic anemia,~myeloproliferative or myelodysplastic syndromes, thrombocytopenia)~* Pregnant or breast-feeding, or is expecting to conceive or donate eggs~during the trial, including 21 days following the last dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omarigliptin (Type: EXPERIMENTAL): Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
- Glimepiride (Type: ACTIVE_COMPARATOR): Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).